Newark, Delaware 19713


Purpose:

The purpose of this study is to examine the effect of mitochondria derived oxidative stress on vascular function in patients with moderate to severe Chronic Kidney Disease.


Study summary:

Chronic Kidney Disease (CKD) patients are at increased risk of cardiovascular disease. Endothelial dysfunction, characterized by a reduced bioavailability in nitric oxide, is an independent predictor of cardiovascular disease in CKD. Increased oxidative stress is a potential cause of endothelial dysfunction in this patient cohort. This study investigates the role that mitochondrial derived oxidative stress plays in CKD related vascular dysfunction. In a controlled, double blinded trial, Stage 3-5 CKD patients will be randomly assigned to receive a 4 week daily dose of a mitochondria targeted antioxidant (MitoQ) or a placebo.


Criteria:

Inclusion Criteria: - Stage 3 - 5 Chronic Kidney Disease Exclusion Criteria: - History of cardiovascular disease; - Current pregnancy; - Uncontrolled hypertension; - Uncontrolled hyperlipidemia; - Current hormone replacement therapy; - Current use of tobacco products; - Elevated liver enzymes; - Current autoimmune disease; - Daily use of of antioxidants >300mg


NCT ID:

NCT02364648


Primary Contact:

Principal Investigator
Danielle L Kirkman, PhD
University of Delaware

Danielle L Kirkman, PhD
Phone: 302 831 4659
Email: dkirkman@udel.edu


Backup Contact:

Email: dge@udel.edu
David G Edwards, PhD


Location Contact:

Newark, Delaware 19713
United States

David Edwards, PhD
Email: dge@udel.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: November 20, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.